• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of October 2


The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of October 2.


Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of October 2.

Number 5: Medicines for Europe has released a new report, prepared by the Economist Intelligence Unit, that attempts to address the problem of medicines shortages in Europe.

Number 4: FDA Commissioner, Dr Scott Gottlieb, announced 2 new initiatives this week. One is aimed at increasing competition for complex generics, and the other streamlines the process for patients to receive investigational drugs for compassionate use.

Number 3: In a new report on drug spending, pharmacy benefit manager Express Scripts says that a group comprising less than 1% of US patients accounts for more than 20% of total pharmacy spending.

Number 2: Allergan is being sued by fellow Irish drug maker, Shire, over its embattled dry eye drug, Restasis.

Number 1: A newly published case report suggests that biosimilar infliximab could present a new treatment option for patients with HIV who develop mycobacterial immune reconstitution inflammatory syndrome.

Finally, last week, our newsletter asked for your input on how suffixes to biosimilars’ names should be addressed. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD.
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Related Content
© 2024 MJH Life Sciences

All rights reserved.